These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 8212747

  • 1. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P, Schmidt G.
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [Abstract] [Full Text] [Related]

  • 2. [Current treatment of supraventricular tachycardia: drug therapy].
    Manz M, Lüderitz B.
    Z Gesamte Inn Med; 1993 Sep; 48(9):430-8. PubMed ID: 8212748
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA, Kuhn RJ, McCaffrey FM.
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [Abstract] [Full Text] [Related]

  • 4. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G.
    Acta Cardiol; 1995 Nov; 50(2):125-34. PubMed ID: 7610735
    [Abstract] [Full Text] [Related]

  • 5. Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
    Manz M, Lüderitz B.
    Eur Heart J; 1993 Sep; 14 Suppl E():91-8. PubMed ID: 8223763
    [Abstract] [Full Text] [Related]

  • 6. Using the right drug: a treatment algorithm for regular supraventricular tachycardias.
    Lévy S, Ricard P.
    Eur Heart J; 1997 May; 18 Suppl C():C27-32. PubMed ID: 9152672
    [Abstract] [Full Text] [Related]

  • 7. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F, Candinas R, Frielingsdorf J.
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [Abstract] [Full Text] [Related]

  • 8. [Effects of diltiazem in supraventricular paroxysmal tachyarrhythmias].
    De Rosa F, Feraco E, Venneri N, Boncompagni F, Curia F, Guzzo D, Plastina F.
    G Ital Cardiol; 1986 Sep; 16(9):776-81. PubMed ID: 3803800
    [Abstract] [Full Text] [Related]

  • 9. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D, Rowland E, O'Nunain S, Shakespeare CF, Poloniecki J, Camm AJ.
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [Abstract] [Full Text] [Related]

  • 10. [Exogenous adenosine as an anti-arrhythmia agent].
    Tebbenjohanns J, Pfeiffer D, Schumacher B, Korte T, Jung W, Lüderitz B.
    Z Kardiol; 1996 Dec; 85 Suppl 6():191-9. PubMed ID: 9064965
    [Abstract] [Full Text] [Related]

  • 11. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG.
    Am J Cardiol; 1996 Jan 25; 77(3):72A-82A. PubMed ID: 8607395
    [Abstract] [Full Text] [Related]

  • 12. Arrhythmias in the intensive care patient.
    Trappe HJ, Brandts B, Weismueller P.
    Curr Opin Crit Care; 2003 Oct 25; 9(5):345-55. PubMed ID: 14508146
    [Abstract] [Full Text] [Related]

  • 13. [Conservative therapy of supraventricular tachycardias].
    Gmeiner R, Sterz H.
    Wien Med Wochenschr; 1984 Oct 31; 134(19-20):443-7. PubMed ID: 6151320
    [Abstract] [Full Text] [Related]

  • 14. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M, Cullen MT, Casadei G.
    Eur Heart J; 1995 Dec 31; 16(12):1943-51. PubMed ID: 8682031
    [Abstract] [Full Text] [Related]

  • 15. [Catheter ablation in supraventricular tachycardia].
    Pitschner HF, Neuzner J.
    Z Kardiol; 1996 Dec 31; 85 Suppl 6():45-60. PubMed ID: 9064982
    [Abstract] [Full Text] [Related]

  • 16. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
    Rae AP.
    Am J Cardiol; 1998 Oct 16; 82(8A):59N-65N. PubMed ID: 9809902
    [Abstract] [Full Text] [Related]

  • 17. [Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia].
    Vester EG.
    Herz; 1997 Jun 16; 22 Suppl 1():40-50. PubMed ID: 9333591
    [Abstract] [Full Text] [Related]

  • 18. [Drug therapy of cardiac arrhythmias 199].
    Dietz A, Manz M.
    Fortschr Med; 1997 Nov 30; 115(33):32, 34-6, 38. PubMed ID: 9480278
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL, Naccarelli GV, Berns E, Dougherty AH.
    Am J Cardiol; 1988 Aug 25; 62(6):44D-55D. PubMed ID: 3136636
    [Abstract] [Full Text] [Related]

  • 20. [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
    Aouate P, Frank R, Fontaine G, Tonet J, Tageddine R, Benassar A, Turlure A, Jacquemin M, Laborde JP.
    Arch Mal Coeur Vaiss; 1995 Dec 25; 88(12):1869-74. PubMed ID: 8729368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.